Search

Your search keyword '"Barbanti, Piero"' showing total 534 results
Start Over Author "Barbanti, Piero"
534 results on '"Barbanti, Piero"'

2. Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study

Author

Barbanti, Piero, Egeo, Gabriella, Proietti, Stefania, d’Onofrio, Florindo, Aurilia, Cinzia, Finocchi, Cinzia, Di Clemente, Laura, Zucco, Maurizio, Doretti, Alberto, Messina, Stefano, Autunno, Massimo, Ranieri, Angelo, Carnevale, Antonio, Colombo, Bruno, Filippi, Massimo, Tasillo, Miriam, Rinalduzzi, Steno, Querzani, Pietro, Sette, Giuliano, Forino, Lorenzo, Zoroddu, Francesco, Robotti, Micaela, Valenza, Alessandro, Camarda, Cecilia, Borrello, Laura, Aguggia, Marco, Viticchi, Giovanna, Tomino, Carlo, Fiorentini, Giulia, Orlando, Bianca, Bonassi, Stefano, and Torelli, Paola

Published
2024
Full Text
View/download PDF

6. Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study

Author

Barbanti, Piero, Aurilia, Cinzia, Egeo, Gabriella, Proietti, Stefania, D’Onofrio, Florindo, Torelli, Paola, Aguggia, Marco, Bertuzzo, Davide, Finocchi, Cinzia, Trimboli, Michele, Cevoli, Sabina, Fiorentini, Giulia, Orlando, Bianca, Zucco, Maurizio, Di Clemente, Laura, Cetta, Ilaria, Colombo, Bruno, di Poggio, Monica Laura Bandettini, Favoni, Valentina, Grazzi, Licia, Salerno, Antonio, Carnevale, Antonio, Robotti, Micaela, Frediani, Fabio, Altamura, Claudia, Filippi, Massimo, Vernieri, Fabrizio, and Bonassi, Stefano

Published
2024
Full Text
View/download PDF

8. Correction to: Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study

Author

Barbanti, Piero, Egeo, Gabriella, Proietti, Stefania, d’Onofrio, Florindo, Aurilia, Cinzia, Finocchi, Cinzia, Di Clemente, Laura, Zucco, Maurizio, Doretti, Alberto, Messina, Stefano, Autunno, Massimo, Ranieri, Angelo, Carnevale, Antonio, Colombo, Bruno, Filippi, Massimo, Tasillo, Miriam, Rinalduzzi, Steno, Querzani, Pietro, Sette, Giuliano, Forino, Lorenzo, Zoroddu, Francesco, Robotti, Micaela, Valenza, Alessandro, Camarda, Cecilia, Borrello, Laura, Aguggia, Marco, Viticchi, Giovanna, Tomino, Carlo, Fiorentini, Giulia, Orlando, Bianca, Bonassi, Stefano, and Torelli, Paola

Published
2024
Full Text
View/download PDF

10. Correction to: Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study

Author

Barbanti, Piero, Aurilia, Cinzia, Egeo, Gabriella, Proietti, Stefania, D’Onofrio, Florindo, Torelli, Paola, Aguggia, Marco, Bertuzzo, Davide, Finocchi, Cinzia, Trimboli, Michele, Cevoli, Sabina, Fiorentini, Giulia, Orlando, Bianca, Zucco, Maurizio, Di Clemente, Laura, Cetta, Ilaria, Colombo, Bruno, di Poggio, Monica Laura Bandettini, Favoni, Valentina, Grazzi, Licia, Salerno, Antonio, Carnevale, Antonio, Robotti, Micaela, Frediani, Fabio, Altamura, Claudia, Filippi, Massimo, Vernieri, Fabrizio, and Bonassi, Stefano

Published
2024
Full Text
View/download PDF

12. Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study

Author

Barbanti, Piero, Egeo, Gabriella, Aurilia, Cinzia, Torelli, Paola, Finocchi, Cinzia, d’Onofrio, Florindo, d’Onofrio, Luigi, Rao, Renata, Messina, Stefano, Di Clemente, Laura, Ranieri, Angelo, Autunno, Massimo, Sette, Giuliano, Colombo, Bruno, Carnevale, Antonio, Aguggia, Marco, Tasillo, Miriam, Zoroddu, Francesco, Frediani, Fabio, Filippi, Massimo, Tomino, Carlo, Proietti, Stefania, and Bonassi, Stefano

Published
2023
Full Text
View/download PDF

13. Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experience

Author

Altamura, Claudia, Brunelli, Nicoletta, Marcosano, Marilena, Aurilia, Cinzia, Egeo, Gabriella, Lovati, Carlo, Favoni, Valentina, Perrotta, Armando, Maestrini, Ilaria, Schiano Di Cola, Francesca, d’Onofrio, Florindo, Finocchi, Cinzia, Bertuzzo, Davide, Bono, Francesco, Ranieri, Angelo, Albanese, Maria, Messina, Roberta, Doretti, Alberto, Di Piero, Vittorio, Cevoli, Sabina, Barbanti, Piero, and Vernieri, Fabrizio

Published
2022
Full Text
View/download PDF

15. Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients

Author

Barbanti, Piero, Egeo, Gabriella, Aurilia, Cinzia, Altamura, Claudia, d’Onofrio, Florindo, Finocchi, Cinzia, Albanese, Maria, Aguggia, Marco, Rao, Renata, Zucco, Maurizio, Frediani, Fabio, Filippi, Massimo, Messina, Roberta, Cevoli, Sabina, Carnevale, Antonio, Fiorentini, Giulia, Messina, Stefano, Bono, Francesco, Torelli, Paola, Proietti, Stefania, Bonassi, Stefano, and Vernieri, Fabrizio

Published
2022
Full Text
View/download PDF

17. Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study

Author

Ornello, Raffaele, Baraldi, Carlo, Guerzoni, Simona, Lambru, Giorgio, Andreou, Anna P., Raffaelli, Bianca, Gendolla, Astrid, Barbanti, Piero, Aurilia, Cinzia, Egeo, Gabriella, Cevoli, Sabina, Favoni, Valentina, Vernieri, Fabrizio, Altamura, Claudia, Russo, Antonio, Silvestro, Marcello, Valle, Elisabetta Dalla, Mancioli, Andrea, Ranieri, Angelo, Alfieri, Gennaro, Latysheva, Nina, Filatova, Elena, Talbot, Jamie, Cheng, Shuli, Holle, Dagny, Scheffler, Armin, Nežádal, Tomáš, Čtrnáctá, Dana, Šípková, Jitka, Matoušová, Zuzana, Casalena, Alfonsina, Maddestra, Maurizio, Viola, Stefano, Affaitati, Giannapia, Giamberardino, Maria Adele, Pistoia, Francesca, Reuter, Uwe, and Sacco, Simona

Published
2022
Full Text
View/download PDF

21. Improvement in diagnostic-therapeutic care pathways for women with migraine: an Italian Delphi panel.

Author

Cevoli, Sabina, Barbanti, Piero, Finocchi, Cinzia, Benedan, Laura, Mariani, Paolo, Orthmann, Nicoletta, Bauleo, Salvatore, Brusa, Paola, Cianci, Dorella, Marozio, Luca, Masseroni, Sara, Sangermani, Roberto, Frediani, Fabio, and Allais, Gianni

Subjects
MEDICAL personnel, GENERAL practitioners, TEENAGE girls, MIGRAINE, PEDIATRIC therapy, MIGRAINE aura
Abstract

Background: Migraine is a highly underestimated and burdensome disease. Real-world studies evidence that migraine is more frequent and severe in women than men. However, to this day, no diagnostic-therapeutic pathways exist to satisfy the specific needs of female patients. Methods: In this study, migraine experts, specialists in women's health, patient, and decision makers, analyzed the diagnostic and therapeutic options for women with migraine across various ages and health conditions within the Italian healthcare system. A Delphi approach was used to formulate statements and achieve a consensus. Results: Gaps in clinical practice were identified, and strategies to accommodate women's needs were proposed. The experts agreed that a socio-behavioral intervention should be planned before any pharmacological treatment in pediatric/adolescent female patients and that the assessment of migraine with aura is considered crucial for adult women requiring contraceptive therapy. Acupuncture emerged as an effective treatment for pregnant and breastfeeding women, and hormone-replacement therapy selection in menopausal patients requires careful consideration to mitigate safety risks. The experts highlighted the absence of literature and guidelines for the management of migraine in women undergoing assisted reproductive procedures or oncological treatment. In light of these observations, the experts advocated the establishment of multidisciplinary collaborations between neurologists/headache specialists and other healthcare professionals, including general practitioners, pediatricians, gynecologists, and oncologists. Comprehensive migraine education for all healthcare professionals potentially involved in managing the disease, including pharmacists, was emphasized. Efforts to increase migraine awareness among women should be prioritized. Conclusion: The insights gained from this Italian consensus study should serve to develop an improved, female-specific pathway to diagnose and treat migraine. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. Sumatriptan‐naproxen sodium in migraine: A review.

Author

Wilcha, Robyn‐Jenia, Afridi, Shazia K., Barbanti, Piero, Diener, Hans Christoph, Jürgens, Tim Patrick, Lanteri‐Minet, Michel, Lucas, Christian, Mawet, Jerôme, Moisset, Xavier, Russo, Antonio, Sacco, Simona, Sinclair, Alexandra J., Sumelahti, Marja‐Liisa, Tassorelli, Cristina, and Goadsby, Peter J.

Subjects
MIGRAINE, SUMATRIPTAN, CLINICAL trials, SODIUM, ADULTS
Abstract

Background: Varied responses to acute migraine medications have been observed, with over one‐third (34.5%) of patients reporting insufficient headache relief. Sumatriptan‐naproxen sodium, a single, fixed‐dose combination tablet comprising sumatriptan 85 mg and naproxen sodium 500 mg, was developed with the rationale of targeting multiple putative mechanisms involved in the pathogenesis of migraine to optimise acute migraine care. Methods: A narrative review of clinical trials investigating sumatriptan‐naproxen sodium for both adults and adolescents was performed in March 2024. Results: Across a total of 14 clinical trials in nine publications, sumatriptan‐naproxen sodium offered greater efficacy for 2‐h pain freedom (14/14) and sustained pain‐free response up to 24 h (13/14) compared with monotherapy and/or placebo for both adult and adolescent study participants with an acceptable and well‐tolerated adverse effect profile. Clinical trial data also demonstrates the effectiveness of sumatriptan‐naproxen sodium in participants with allodynia, probable migraine, menstrual‐related migraine and those with poor responses to acute, non‐specific, migraine medication. Conclusions: Multi‐mechanistic therapeutic agents offer an opportunity to optimise acute medications by targeting multiple mediators involved in the pathogenesis of migraine. Sumatriptan‐naproxen sodium resulted in greater initial and sustained pain freedom, compared with either sumatriptan, naproxen‐sodium and/or placebo, for the treatment of single or multiple attacks of migraine across both adult and adolescent study populations. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. Calcitonin Gene-Related Peptide Monoclonal Antibodies: Key Lessons from Real-World Evidence.

Author

Orlando, Bianca, Egeo, Gabriella, Aurilia, Cinzia, Fiorentini, Giulia, and Barbanti, Piero

Subjects
CALCITONIN gene-related peptide, ERENUMAB, MIGRAINE, TREATMENT effectiveness, DATA extraction
Abstract

Background: The advent of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway has transformed the management of migraine, offering newfound optimism for clinicians and individuals with episodic migraine (EM) and chronic migraine (CM). While randomized controlled trials (RCTs) have provided crucial insights into the effectiveness and safety profiles of these treatments, their translation into real-world clinical practice remains a challenge. Objective: This review aims to conduct a comprehensive assessment of real-world studies, offering valuable insights tailored for practical application in clinical settings. Methods: We conducted a comprehensive literature search in PubMed, SCOPUS, and MEDLINE for real-life studies on erenumab, fremanezumab, and galcanezumab. Abstracts underwent rigorous screening by two reviewers for relevance. Data extraction from selected articles was performed using a standardized form, with verification by a second reviewer. Data synthesis was narrative, following PRISMA guidelines. Results: Our search included 61 pertinent studies conducted between 2019 and 1 March 2024. Real-world study designs demonstrated notable variability in the selection and inclusion of migraine patients, influenced by factors such as attack frequency, data collection criteria, and primary/secondary objectives. Key findings commonly reported considerable improvements in efficacy outcomes (migraine frequency, analgesic use, pain severity, and disability), high responder rates, and optimal safety and tolerability profiles. Conclusions: Real-world evidence underscores the role of anti-CGRP mAbs as targeted therapies for both CM and EM patients. The overall results indicate that the effectiveness and tolerability of anti-CGRP mAbs in real-world applications may exceed those observed in RCTs, an extraordinary finding in clinical neurology. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

25. Evaluating the Effectiveness, Tolerability, and Safety of Eptinezumab in High-Frequency and Chronic Migraine in Real World: EMBRACE—The First Italian Multicenter, Prospective, Real-Life Study.

Author

Barbanti, Piero, Orlando, Bianca, Egeo, Gabriella, d'Onofrio, Florindo, Doretti, Alberto, Messina, Stefano, Autunno, Massimo, Messina, Roberta, Filippi, Massimo, Fiorentini, Giulia, Rotondi, Cristina, Bonassi, Stefano, and Aurilia, Cinzia

Subjects
*IMPACT testing, *MIGRAINE, *PEPTIDES, *TREATMENT failure, *CONTENT analysis
Abstract

We conducted a multicenter, prospective study (EMBRACE) evaluating the real-life effectiveness, safety, and tolerability of eptinezumab (100 mg/300 mg)—a monoclonal antibody targeting the calcitonin-gene-related peptide (anti-CGRP mAb)—in high-frequency episodic migraine (HFEM) or chronic migraine (CM). The primary endpoint was the change in monthly migraine days (MMD) for HFEM or monthly headache days (MHD) for CM at weeks 9–12 compared to baseline. The secondary endpoints included changes in monthly analgesic intake (MAI), Numerical Rating Scale (NRS), Headache Impact Test (HIT-6), Migraine Disability Assessment Scale (MIDAS), Migraine Interictal Burden Scale (MIBS-4), and responder rates. The safety analysis involved 44 subjects; the effectiveness analysis included 26 individuals. Eptinezumab was well-tolerated. In CM patients, eptinezumab significantly reduced MHD (−16.1 ± 9.9, p < 0.001), MAI, NRS, HIT-6, MIDAS, and MIBS-4. In HFEM patients, it significantly reduced NRS, HIT-6, MIDAS, and MIBS-4, though reductions in MMD (−3.3 ± 4.5) and MAI were not statistically significant. Overall, ≥50% and ≥75% response rates were 61.5% and 30.8%, respectively (60% and 30% in non-responders to subcutaneous anti-CGRP mAbs). The clinical change was rated as much or very much improved by 61.0% of the patients. Eptinezumab demonstrated high effectiveness, safety, and tolerability in real-life among hard-to-treat migraine patients with multiple treatment failures, including anti-CGRP mAbs. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

31. Correction to: Practical and clinical utility of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: a post hoc analysis of the randomized, sham-controlled, double-blind PRESTO trial

Author

Grazzi, Licia, Tassorelli, Cristina, de Tommaso, Marina, Pierangeli, Giulia, Martelletti, Paolo, Rainero, Innocenzo, Geppetti, Pierangelo, Ambrosini, Anna, Sarchielli, Paola, Liebler, Eric, Barbanti, Piero, and on Behalf of the PRESTO Study Group

Published
2019
Full Text
View/download PDF

34. Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3‐month observational, longitudinal, cohort, multicenter, Italian real‐life study

Author

Vernieri, Fabrizio, Altamura, Claudia, Brunelli, Nicoletta, Costa, Carmelina Maria, Aurilia, Cinzia, Egeo, Gabriella, Fofi, Luisa, Favoni, Valentina, Lovati, Carlo, Bertuzzo, Davide, d'Onofrio, Florindo, Doretti, Alberto, Di Fiore, Paola, Finocchi, Cinzia, Schiano Di Cola, Francesca, Ranieri, Angelo, Colombo, Bruno, Bono, Francesco, Albanese, Maria, Cevoli, Sabina, Barbanti, Piero, GARLIT Study Group, Filippi, Massimo, Vernieri, Fabrizio, Altamura, Claudia, Brunelli, Nicoletta, Costa, Carmelina Maria, Aurilia, Cinzia, Egeo, Gabriella, Fofi, Luisa, Favoni, Valentina, Lovati, Carlo, Bertuzzo, Davide, D'Onofrio, Florindo, Doretti, Alberto, Di Fiore, Paola, Finocchi, Cinzia, Schiano Di Cola, Francesca, Ranieri, Angelo, Colombo, Bruno, Bono, Francesco, Albanese, Maria, Cevoli, Sabina, Barbanti, Piero, GARLIT Study, Group, and Filippi, Massimo

Subjects
Adult, Male, medicine.medical_specialty, Migraine Disorders, Triptans, Calcitonin gene-related peptide, Antibodies, Monoclonal, Humanized, Chronic Migraine, Double-Blind Method, Internal medicine, medicine, galcanezumab, Humans, Mass index, CGRP, real-life, Prospective Studies, Rapid response, business.industry, Middle Aged, medicine.disease, Comorbidity, Treatment Outcome, Italy, Neurology, Migraine, Female, Observational study, monoclonal antibodies, Neurology (clinical), chronic migraine, business, medicine.drug
Abstract

Background and purpose A rapid response to preventive therapy is of pivotal importance in severely disabled patients with chronic migraine (CM) and diverse preventive treatment failures. This prospective, observational, multicenter real-life study aimed at investigating the effectiveness of galcanezumab in the first 3 months of treatment of CM patients at 14 Italian headache centers. Methods All consecutive adult patients with CM diagnosis with the clinical indication for galcanezumab were considered. We collected patients' baseline characteristics, monthly headache days, monthly painkiller intake, migraine clinical characteristics, and disability scale scores during a 1-month run-in period (baseline) and the first 3 months of therapy. Possible predictive factors of treatment were considered. Results A total of 156 patients (82.4% female, aged 47.3 +/- 12.3 years) were enrolled. The 65 (41.7%) patients with a consecutive >= 50% response rate (RR) in the 3 months of therapy presented a lower body mass index (p = 0.004) and more frequently presented unilateral migraine pain (p = 0.002) and good response to triptans (p = 0.003). Persistent conversion from CM to episodic migraine was observed in 55.8% (87/156) of patients. They more frequently presented a good response to triptans (p = 0.003) and unilateral pain (p = 0.046). At baseline, 131 of 156 (83.9%) patients presented medication overuse (MO). Of these, 61.8% (81/131) no longer displayed MO consistently during the 3 months. These patients were more frequently responders to triptans (p = 0.002) and less frequently suffered from gastrointestinal comorbidity (p = 0.007). Conclusions Unilateral pain, good response to triptans, and normal weight may be associated with a persistent positive response in the first 3 months of therapy with galcanezumab in CM patients.

Published
2021

39. Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world

Author

Caronna, Edoardo, Gallardo, Victor José, Egeo, Gabriella, Vázquez, Manuel Millán, Castellanos, Candela Nieves, Membrilla, Javier A, Vaghi, Gloria, Rodríguez-Montolio, Joana, Fabregat Fabra, Neus, Sánchez-Caballero, Francisco, Jaimes Sánchez, Alex, Muñoz-Vendrell, Albert, Oliveira, Renato, Gárate, Gabriel, González-Osorio, Yésica, Guisado-Alonso, Daniel, Ornello, Raffaele, Thunstedt, Cem, Fernández-Lázaro, Iris, Torres-Ferrús, Marta, Alpuente, Alicia, Torelli, Paola, Aurilia, Cinzia, Pére, Raquel Lamas, Castrillo, Maria José Ruiz, Icco, Roberto De, Sances, Grazia, Broadhurst, Sarah, Ong, Hui Ching, García, Andrea Gómez, Campoy, Sergio, Sanahuja, Jordi, Cabral, Goncalo, Beltrán Blasco, Isabel, Waliszewska-Prosół, Marta, Pereira, Liliana, Layos-Romero, Almudena, Luzeiro, Isabel, Dorado, Laura, Álvarez Escudero, María Rocio, May, Arne, López-Bravo, Alba, Martins, Isabel Pavão, Sundal, Christina, Irimia, Pablo, Lozano Ros, Alberto, Gago-Veiga, Ana Beatriz, Juanes, Fernando Velasco, Ruscheweyh, Ruth, Sacco, Simona, Cuadrado-Godia, Elisa, García-Azorín, David, Pascual, Julio, Gil-Gouveia, Raquel, Huerta-Villanueva, Mariano, Rodriguez-Vico, Jaime, Viguera Romero, Javier, Obach, Victor, Santos-Lasaosa, Sonia, Ghadiri-Sani, Mona, Tassorelli, Cristina, Díaz-de-Terán, Javier, Díaz Insa, Samuel, Oria, Carmen González, Barbanti, Piero, and Pozo-Rosich, Patricia

Abstract

BackgroundAnti-CGRP monoclonal antibodies (anti-CGRP MAbs) are approved and available treatments for migraine prevention. Patients do not respond alike and many countries have reimbursement policies, which hinder treatments to those who might respond. This study aimed to investigate clinical factors associated with good and excellent response to anti-CGRP MAbs at 6 months.MethodsEuropean multicentre, prospective, real-world study, including high-frequency episodic or chronic migraine (CM) patients treated since March 2018 with anti-CGRP MAbs. We defined good and excellent responses as ≥50% and ≥75% reduction in monthly headache days (MHD) at 6 months, respectively. Generalised mixed-effect regression models (GLMMs) were used to identify variables independently associated with treatment response.ResultsOf the 5818 included patients, 82.3% were females and the median age was 48.0 (40.0–55.0) years. At baseline, the median of MHD was 20.0 (14.0–28.0) days/months and 72.2% had a diagnosis of CM. At 6 months (n=4963), 56.5% (2804/4963) were good responders and 26.7% (1324/4963) were excellent responders. In the GLMM model, older age (1.08 (95% CI 1.02 to 1.15), p=0.016), the presence of unilateral pain (1.39 (95% CI 1.21 to 1.60), p<0.001), the absence of depression (0.840 (95% CI 0.731 to 0.966), p=0.014), less monthly migraine days (0.923 (95% CI 0.862 to 0.989), p=0.023) and lower Migraine Disability Assessment at baseline (0.874 (95% CI 0.819 to 0.932), p<0.001) were predictors of good response (AUC of 0.648 (95% CI 0.616 to 0.680)). These variables were also significant predictors of excellent response (AUC of 0.691 (95% CI 0.651 to 0.731)). Sex was not significant in the GLMM models.ConclusionsThis is the largest real-world study of migraine patients treated with anti-CGRP MAbs. It provides evidence that higher migraine frequency and greater disability at baseline reduce the likelihood of responding to anti-CGRP MAbs, informing physicians and policy-makers on the need for an earlier treatment in order to offer the best chance of treatment success.

Published
2024
Full Text
View/download PDF

43. Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures. The multicenter, prospective, real-life FRIEND2 study.

Author

Barbanti, Piero, primary, Egeo, Gabriella, additional, Aurilia, Cinzia, additional, Torelli, Paola, additional, Finocchi, Cinzia, additional, d'Onofrio, Florindo, additional, d'Onorio, Luigi, additional, Rao, Renata, additional, Messina, Stefano, additional, Clemente, Laura Di, additional, Ranieri, Angelo, additional, Autunno, Massimo, additional, Sette, Giuliano, additional, Colombo, Bruno, additional, Carnevale, Antonio, additional, Aguggia, Marco, additional, Tasillo, Miriam, additional, Zoroddu, Francesco, additional, Frediani, Fabio, additional, Filippi, Massimo, additional, Fiorentini, Giulia, additional, Tomino, Carlo, additional, Proietti, Stefania, additional, and Bonassi, Stefano, additional

Published
2023
Full Text
View/download PDF

46. The evaluation of difficulties with work-related activities caused by migraine: towards a specific questionnaire

Author

Covelli, Venusia, Guastafierro, Erika, Raggi, Alberto, Grazzi, Licia, Leonardi, Matilde, Scaratti, Chiara, Bartolini, Marco, Viticchi, Giovanna, Cevoli, Sabina, Pierangeli, Giulia, Tedeschi, Gioacchino, Russo, Antonio, Barbanti, Piero, Aurilia, Cinzia, Lovati, Carlo, Giani, Luca, Fredian, Fabio, Di Fiore, Paola, Bono, Francesco, Rapisarda, Laura, and D’Amico, Domenico

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results